Sanofi’s SNY stock has declined 10.2% in the past three months. However, a lot of this price decline was due to the downtrend of the overall drug and biotech sector, which performed poorly in the past ...

Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

After hitting a regulatory roadblock in 2022, Sanofi’s consumer healthcare business Opella has secured the FDA’s blessing to ...

Sanofi possesses a leading vaccine portfolio that drives the top line. Several new drugs have ... in all key markets and lower sales from mature products are hurting sales. Other headwinds include ...

J.P. Morgan analyst Richard Vosser maintained a Hold rating on Sanofi (SNYNF – Research Report) today and set a price target of €105.00. The ...

Dupixent: A Key Top-Line Driver for SNY Sanofi’s immunology ... backed by its innovation efforts. Sanofi’s new products like novel recombinant factor VIII therapy, Altuviiio, respiratory ...